|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Asthma |
|
Bronchospasm, exercise- induced |
| |
|
|
SIDE EFFECTS:
|
|
anaphylactoid reactions |
|
angina |
|
angioedema |
|
anxiety |
|
arrhythmia exacerbation |
|
bronchospasm |
|
cough |
|
diaphoresis |
|
dizziness |
|
drowsiness |
|
dyspepsia |
|
epistaxis |
|
excitability |
|
flushing |
|
headache |
|
hoarseness |
|
hostility |
|
hyperglycemia |
|
hyperkinesis |
|
hypertension |
|
hypokalemia |
|
hypotension |
|
insomnia |
|
irritability |
|
maculopapular rash |
|
muscle cramps |
|
nausea/vomiting |
|
nightmares |
|
palpitations |
|
peripheral vasodilation |
|
QT prolongation |
|
restlessness |
|
sinus tachycardia |
|
ST-T wave changes |
|
syncope |
|
throat irritation |
|
tremor |
|
urinary retention |
|
urticaria |
|
xerostomia |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
acute bronchospasm |
|
breast-feeding |
|
cardiac arrhythmias |
|
cardiac disease |
|
children |
|
coronary artery disease |
|
diabetes mellitus |
|
elderly |
|
hypertension |
|
hyperthyroidism |
|
hypokalemia |
|
pheochromocytoma |
|
pregnancy |
|
QT prolongation |
|
seizure disorder |
|
seizures |
|
status asthmaticus |
|
tachycardia |
|
thyrotoxicosis |
|
|
ADULT DOSE:
|
|
Severe bronchospasm and status asthmaticus-Intramuscular, 500 mcg (0.5 mg) (base) (8 mcg per kg of body weight) every four hours as required .
Intravenous bolus (over two to five minutes), 250 mcg (0.25 mg) (base) (4 mcg per kg of body weight, repeated after fifteen minutes if necessary .
Intravenous infusion (continuous), 5 mcg (0.005 mg) (base) per minute, increased to 10 mcg per minute and then 20 mcg per minute at fifteen- to thirty-minute intervals, if necessary . |
|
MAXIMUM ADULT DOSE:
|
|
Intramuscular: 2 mg (base) per day .
Intravenous bolus: 1 mg (base) per day .
|
|
PEDIATRIC DOSE:
|
|
Dosage has not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|